GHRP-6

GHRP-6 Molecular Structure & Chemical Properties

GHRP-6 peptide represents one of the earliest and most extensively studied growth hormone secretagogues, first developed in the 1980s as a synthetic analog of met-enkephalin. Unlike its opioid precursor, GHRP-6 lacks opioid activity but demonstrates potent growth hormone-releasing effects through activation of the ghrelin receptor system. This hexapeptide has sustained over three decades of scientific interest due to its unique pharmacological properties, including oral bioavailability uncommon among peptides and demonstrated cytoprotective effects across multiple organ systems in preclinical research. The peptide’s incorporation of D-amino acids contributes to enhanced stability compared to naturally occurring peptide sequences, enabling diverse routes of administration in experimental models.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure contains two D-amino acids (D-Trp at position 2 and D-Phe at position 5), which confer resistance to peptidase degradation and contribute to its unusual oral activity for a peptide molecule. This structural modification distinguishes GHRP-6 from naturally occurring peptide hormones.

GHRP-6 Mechanism of Action

GHRP-6 peptide exerts its biological effects through activation of at least two distinct receptor systems – the growth hormone secretagogue receptor type 1a (GHS-R1a, also known as the ghrelin receptor) and the CD36 scavenger receptor. This dual-receptor engagement enables GHRP-6 to produce effects that extend beyond simple growth hormone stimulation, encompassing direct cytoprotective actions independent of the growth hormone axis.

Primary Receptor Pathways

GHS-R1a Activation – Growth Hormone Release

GHRP-6 functions as a potent agonist of the GHS-R1a receptor, triggering growth hormone secretion from pituitary somatotrophs through mechanisms distinct from growth hormone-releasing hormone (GHRH). Research has demonstrated that GHRP-6 stimulates phosphatidylinositol turnover in human pituitary cells, activating protein kinase C and mobilizing intracellular calcium reserves. This mechanism results in:

• Pulsatile growth hormone release mimicking physiological secretion patterns
• Enhanced responsiveness when combined with GHRH (synergistic effects)
• Activation independent of cyclic AMP pathways
• Functional antagonism of somatostatin-mediated growth hormone suppression

Studies in healthy human volunteers confirmed dose-dependent growth hormone release following intravenous administration, with peak responses observed 15-30 minutes post-dose.

CD36 Receptor Signaling – Cytoprotection

Beyond growth hormone secretion, GHRP-6 binds to CD36, a scavenger receptor abundantly expressed in cardiac tissue, vascular endothelium, and wound granulation tissue. CD36 activation by GHRP-6 triggers:

• PI3K/AKT1 pathway activation promoting cell survival
• Upregulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha)
• Enhanced cellular resistance to oxidative stress and apoptosis
• Modulation of inflammatory response pathways

This CD36-mediated mechanism accounts for cytoprotective effects observed in cardiac ischemia-reperfusion models and wound healing studies, occurring independently of growth hormone elevation.

Antioxidant Defense Mechanisms

Research in multiple organ injury models has demonstrated that GHRP-6 enhances antioxidant defense systems through:

• Reduction of reactive oxygen species generation
• Preservation of endogenous antioxidant enzyme activity
• Protection against oxidant-induced cellular damage
• Mitochondrial function stabilization during metabolic stress

These antioxidant effects appear particularly relevant in cardiac protection studies, where GHRP-6 reduced markers of oxidative damage following ischemia-reperfusion injury.

Anti-Inflammatory Signaling

GHRP-6 peptide modulates inflammatory cascades through multiple pathways:

• Attenuation of pro-inflammatory cytokine expression (TNF-alpha, IL-6)
• Reduction of NF-kappa-B pathway activation
• Decreased myeloperoxidase activity in damaged tissues
• Modulation of immune cell infiltration at injury sites

Studies in wound healing models documented reduced inflammatory cell infiltration and accelerated resolution of the inflammatory phase with GHRP-6 treatment.

Anti-Fibrotic Actions

Research has identified GHRP-6’s ability to modulate fibrotic processes through:

• Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma)
• Reduction of transforming growth factor-beta-1 (TGF-beta-1) expression
• Decreased collagen deposition in chronic injury models
• Prevention of hypertrophic scar formation in animal models

These anti-fibrotic effects have been documented in liver fibrosis models and cutaneous wound healing studies.

GHRP-6 Research Applications & Key Findings

Cardiovascular Research

Myocardial Infarction Protection

Extensive research in porcine and rodent models has examined GHRP-6’s cardioprotective effects in acute myocardial infarction. Key findings from controlled studies include:

• 78% reduction in infarct mass in porcine models when administered during reperfusion (compared to saline controls)
• Preservation of ventricular wall thickness and reduction of pathological Q-wave formation
• Decreased serum creatine kinase-MB and C-reactive protein levels
• Prevention of cardiomyocyte apoptosis through Bcl-2/Bax ratio modulation

Studies using electron microscopy revealed that GHRP-6 preserved mitochondrial ultrastructure and prevented myofibril fragmentation during ischemic episodes.

Dilated Cardiomyopathy and Heart Failure

Research in doxorubicin-induced cardiomyopathy models demonstrated:

• Prevention of progressive ventricular dilation and systolic dysfunction
• Maintenance of ejection fraction near baseline levels during cardiotoxic drug exposure
• Significant reduction (over 50%) in cardiomyocyte death compared to vehicle treatment
• Protection of cardiac ultrastructure including sarcolemmal and mitochondrial preservation

Studies in chronic heart failure models showed improved cardiac function and reduced stress hormone elevation with GHRP-6 administration.

Cardiac Fibrosis Reduction

Investigations in spontaneously hypertensive rat models revealed:

• Decreased interstitial and perivascular collagen deposition
• Reduced myocardial hydroxyproline content
• Increased matrix metalloproteinase activity facilitating fibrosis resolution
• Attenuation of ventricular hypertrophy progression

Wound Healing and Tissue Repair Research

Cutaneous Wound Closure

Controlled studies in rat full-thickness wound models documented:

• Accelerated wound closure rates evident within 24 hours of treatment initiation
• Enhanced collagen organization and extracellular matrix reconstitution
• Improved angiogenesis with increased CD31-positive endothelial cells
• Reduced inflammatory cell infiltration during healing phases

Topical application of GHRP-6 (400 mcg/mL formulation) achieved faster closure than vehicle controls across multiple experimental protocols.

Hypertrophic Scar Prevention

Research using the rabbit ear hypertrophic scar model demonstrated:

• Dramatic reduction in exuberant scar formation when applied during early wound healing
• Decreased scar elevation index compared to untreated controls
• Modulation of fibrogenic cytokine expression at wound sites
• Improved esthetic outcomes through organized collagen deposition

Effects were preventive rather than therapeutic, showing efficacy when initiated early but minimal impact on established hypertrophic scars.

Multiple Organ Protection Research

Hepatic Ischemia-Reperfusion Injury

Studies in hepatic vessel occlusion models showed:

• Truncation of liver damage markers by 50-85% compared to controls
• Preservation of hepatic architecture during ischemia-reperfusion episodes
• Reduced inflammatory infiltration in hepatic tissue
• Protection extended to remote organs (kidneys, lungs) in systemic injury models

Gastrointestinal Protection

Research in stress-induced gastric injury models demonstrated:

• Protection against water immersion stress-induced mucosal damage
• Maintenance of gastric barrier function during metabolic stress
• Potential applications in inflammatory bowel disease models (preliminary data)
• Cytoprotective effects in intestinal epithelial cell cultures

Neuroprotection Research

Stroke and Cerebral Ischemia

Investigations in stroke models have examined:

• Reduction in brain lesion volumes following induced cerebral ischemia
• Preservation of memory function when administered post-stroke
• Inhibition of neuronal apoptosis in affected brain regions
• Anti-inflammatory effects in central nervous system tissue

Research identified ghrelin receptor expression in the substantia nigra, suggesting potential relevance for Parkinson’s disease research, though human applications remain unexplored.

GHRP-6 Pharmacokinetics & Metabolism

Absorption & Distribution

GHRP-6 exhibits unusual pharmacokinetic properties for a peptide, demonstrated in both preclinical models and a Phase I human pharmacokinetic study. Following intravenous administration to nine healthy male volunteers at doses of 100-400 mcg/kg:

• Bi-exponential disposition kinetics with rapid distribution phase
• Distribution half-life of approximately 7.6 minutes
• Dose-proportional increases in area under the curve (AUC)
• Well-tolerated across all dose levels without serious adverse events

Despite being a peptide, GHRP-6 demonstrates oral bioavailability in animal models (approximately 0.3% in published studies), though this route exhibits markedly reduced efficiency compared to injectable administration. The peptide distributes systemically within 15-30 minutes following administration in animal studies.

Metabolism & Elimination

The metabolic fate of GHRP-6 has been characterized primarily through human pharmacokinetic studies:

• Elimination half-life of 2.5 hours (range 1.4-3.6 hours) in healthy volunteers
• Bi-compartmental model best fits observed plasma concentration-time profiles
• Clearance from plasma proceeds through enzymatic peptide degradation
• Low systemic clearance observed relative to other peptides of similar size

Limited data suggest biliary excretion may contribute to elimination in some subjects, based on concentration patterns observed during extended monitoring periods. The specific peptidases responsible for GHRP-6 degradation have not been fully characterized.

Excretion Pathways

Available pharmacokinetic data indicate:

• Plasma concentrations fall below quantification limits (5 ng/mL) by 12 hours post-administration
• Likely renal elimination of peptide fragments following enzymatic degradation
• No evidence of accumulation with chronic dosing in animal models
• Complete clearance supports intermittent dosing strategies in research protocols

The relatively short elimination half-life requires multiple daily administrations to maintain elevated concentrations in experimental models, though biological effects may persist beyond measurable plasma levels due to receptor-mediated signaling cascade activation.

GHRP-6 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed GHRP-6 across diverse dose ranges depending on species, model, and experimental objectives:

• Human studies: 100-400 mcg/kg intravenous bolus (Phase I pharmacokinetic trial)
• Porcine models: 400 mcg/kg used in cardiac protection studies
• Rat studies: 10-400 mcg/kg depending on route and application (most common: 100-400 mcg/kg)
• Cell culture studies: Concentrations ranging from nanomolar to micromolar depending on assay

Important: These are experimental doses used in animal studies and controlled human pharmacokinetic research. These doses cannot be extrapolated to other species or therapeutic applications due to significant differences in metabolism, receptor density, pharmacokinetic profiles, and peptide degradation rates across species. Species-specific factors profoundly influence both efficacy and safety profiles, and no therapeutic dosing guidelines exist for any medical condition.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical studies:

• Intravenous injection – Most common in controlled pharmacokinetic and efficacy studies; provides predictable systemic delivery
• Intraperitoneal injection – Frequently used in rodent organ protection studies
• Subcutaneous injection – Employed in chronic dosing protocols and growth hormone release studies
• Topical application – Used in wound healing research (400 mcg/mL formulation in carrier gel)
• Oral administration – Demonstrated activity despite peptide structure, though with very low bioavailability

The choice of administration route in research depends on the experimental endpoint, with systemic routes preferred for cardiac and neurological studies and topical application used for dermal wound healing research.

Common Model Organisms

GHRP-6 has been studied across multiple species and experimental systems:

• Humans – Limited to one Phase I pharmacokinetic and safety trial (nine healthy male volunteers)
• Pigs – Used extensively in cardiac ischemia-reperfusion studies due to cardiovascular similarity to humans
• Rats – Primary research model for wound healing, organ protection, and chronic toxicity studies (Wistar, Sprague-Dawley strains)
• Rabbits – Employed in hypertrophic scar research using the rabbit ear model
• Mice – Used in metabolic studies and body composition research
• Cell cultures – Human pituitary somatotroph cells, cardiomyocytes (H9c2 line), intestinal epithelial cells (IEC-6), colonic cancer cells (HT29)

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite three decades of preclinical research and one Phase I human trial, GHRP-6 faces substantial translational barriers that limit its research utility and prevent clinical application.

Lack of Clinical Efficacy Data

The most significant limitation is the near-complete absence of human efficacy trials:

• Only one published human study exists – a Phase I pharmacokinetic and safety trial in nine healthy volunteers
• No Phase II dose-finding studies in patient populations
• No Phase III randomized controlled trials for any indication
• No published data on efficacy for cardiac protection, wound healing, or any therapeutic application in humans
• Optimal human dosing for therapeutic effects completely unknown
• Long-term human safety profile unestablished beyond single-dose administration

The extensive preclinical data cannot substitute for controlled human clinical trials to establish safety and efficacy.

Mechanistic Understanding Gaps

Several fundamental aspects of GHRP-6’s mechanism require clarification:

• Relative contribution of GHS-R1a versus CD36 pathways to specific biological outcomes remains unclear
• Whether cytoprotective effects require growth hormone elevation or occur independently via CD36 activation
• Downstream signaling cascades following receptor activation incompletely characterized
• Tissue-specific receptor distribution and functional responses not fully mapped
• Optimal timing of administration relative to injury onset for maximal protective effects undefined

Long-Term Safety Considerations

Critical safety questions remain unanswered even in animal models:

• Chronic use effects beyond several weeks inadequately studied
• Potential for tissue growth abnormalities with extended administration unknown
• Effects on existing cardiovascular disease or cancer progression uninvestigated
• Interaction potential with commonly prescribed medications uncharacterized
• Reproductive and developmental toxicity studies limited
• Immunogenicity potential with repeated administration unclear

Regulatory & Competitive Sport Status

FDA Position

GHRP-6 has not received FDA approval for any indication:

• Classified as an unapproved new drug substance
• Not recognized as Generally Recognized as Safe (GRAS)
• Not legally available for pharmacy compounding in the United States
• FDA warning letters issued to compounding pharmacies using GHRP-6 and GHRP-2

The FDA explicitly stated in a 2019 warning letter that “Growth Hormone Releasing Peptide 2 (GHRP-2) and Growth Hormone Releasing Peptide 6 (GHRP-6) were not nominated with adequate support for FDA to evaluate the substances” for inclusion on the bulk substances list for compounding.

WADA Prohibition

The World Anti-Doping Agency classifies GHRP-6 as a prohibited substance:

• Listed under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)
• Specifically identified among growth hormone-releasing peptides (GHRPs) including GHRP-1, GHRP-2, and GHRP-6
• Prohibited at all times (both in-competition and out-of-competition)
• No Therapeutic Use Exemptions (TUEs) available
• Detection methods established for anti-doping testing purposes

Athletes testing positive for GHRP-6 face suspension and disqualification from competition under international anti-doping rules.

Research Classification: GHRP-6 is available only for laboratory research use by qualified institutions. It is not intended for human consumption, medical use, veterinary applications, or athletic performance enhancement. All research must be conducted under appropriate ethical oversight, institutional review board approval, and regulatory compliance with applicable laws and regulations.

References

1. Berlanga-Acosta, J., Abreu-Cruz, A., Garcia Del Barco Herrera, D., Mendoza-Mari, Y., Rodriguez-Ulloa, A., Garcia-Ojalvo, A., Falcon-Cama, V., Hernandez-Bernal, F., Beichen, Q., & Guillen-Nieto, G. (2017). Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clinical Medicine Insights: Cardiology, 11, 1179546817694558. PubMed
   
2. Bowers, C.Y., Reynolds, G.A., Durham, D., Barrera, C.M., Pezzoli, S.S., & Thorner, M.O. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 70(4), 975-982. PubMed
   
3. Small, C.J., & Bloom, S.R. (2004). The therapeutic potential of ghrelin and ghrelin receptor agonists. Current Opinion in Pharmacology, 4(6), 589-593.
4. Cabrales, A., Gil, J., Fernandez, E., Valenzuela, C., Hernandez, F., Garcia, I., Hernandez, A., Besada, V., Reyes, O., Padron, G., Berlanga, J., Guillen, G., & Gonzalez, L.J. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European Journal of Pharmaceutical Sciences, 48(1-2), 40-46. PubMed
   
5. Granado, M., Garcia-Caceres, C., Tuda, M., Frago, L.M., Chowen, J.A., & Argente, J. (2010). The Positive Effects of Growth Hormone-Releasing Peptide-6 on Weight Gain and Fat Mass Accrual Depend on the Insulin/Glucose Status. Endocrinology, 151(5), 2008-2018.
6. Smith, R.G., Van der Ploeg, L.H., Howard, A.D., Feighner, S.D., Cheng, K., Hickey, G.J., Wyvratt, M.J., Fisher, M.H., Nargund, R.P., & Patchett, A.A. (1997). Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 18(5), 621-645.
7. Berlanga, J., Cibrian, D., Guillen, G., Freyre, F., Alba, J.S., Lopez-Saura, P., Merino, N., Aldama, A., Quintela, A.M., Triana, M.E., Montequin, J.F., Ajamieh, H., Urquiza, D., Ahmed, N., & Fernandez-Montequin, J.I. (2007). Growth-hormone-releasing peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats. Biotecnologia Aplicada, 24(3-4), 2.
8. Berlanga-Acosta, J., Playford, R.J., Mandir, N., & Goodlad, R.A. (2001). Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut, 48(6), 803-807. PubMed
   
9. Benso, A., Broglio, F., Aimaretti, G., Lucatello, B., Lanfranco, F., Ghigo, E., & Grottoli, S. (2004). Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. European Journal of Endocrinology, 151(6), 733-740. PubMed
   
10. Berlanga-Acosta, J., Cibrian, D., Valiente-Mustelier, J., Suarez-Alba, J., Garcia-Ojalvo, A., Falcon-Cama, V., Jiang, B., Wang, L., & Guillen-Nieto, G. (2024). Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Frontiers in Pharmacology, 15, 1402138. PubMed
    
11. Delgado-Rubin de Celix, A., Pena, C., Chowen, J.A., Argente, J., & Frago, L.M. (2009). Growth hormone-releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity. Journal of Neurochemistry, 109(3), 1071-1083.
12. Mendoza-Mari, Y., Fernandez-Mayola, M., Aguilera-Barreto, A., Garcia-Ojalvo, A., Bermudez-Alvarez, Y., Mir-Benitez, A.J., & Berlanga-Acosta, J. (2016). Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plastic Surgery International, 2016, 4361702. PubMed
    
13. Xu, X.B., Pang, J.J., Cao, J.M., Ni, C., Xu, R.K., Peng, X.Z., Yu, X.X., Guo, S., Chen, M.C., & Chen, C. (2005). GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. American Journal of Physiology – Heart and Circulatory Physiology, 289(4), H1643-H1651. PubMed
    
14. Granado, M., Priego, T., Martin, A.I., Villanueva, M.A., & Lopez-Calderon, A. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology – Endocrinology and Metabolism, 288(3), E486-E492.
15. Pihoker, C., Kearns, G.L., French, D., & Bowers, C.Y. (1998). Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. Journal of Clinical Endocrinology and Metabolism, 83(4), 1168-1172. PubMed
    
16. Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. European Journal of Endocrinology, 136(5), 445-460. PubMed
    
17. Ishida, J. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-41.
18. Alba, J.S., Escarpanter, J., Casacó, A., Berlanga, J., García, I., Playford, R.J., Goodlad, R.A., & González, L.J. (2006). Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clinical Science, 110(5), 563-573. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. GHRP-6 is intended for laboratory research use only.